<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000044895"><TermName>XR9576</TermName><TermDefinition><DefinitionText>A substance that is being studied in the treatment of cancer. It may help tumor cells respond again to drugs they have become resistant (unable to respond) to. XR9576 is a type of multidrug resistance inhibitor and a type of P-glycoprotein antagonist. Also called tariquidar.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><SpanishTermName>XR9576</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Puede ayudar a que las células tumorales respondan nuevamente a los medicamentos a los que se han vuelto resistentes (incapaces de responder). XR9576 es un tipo de inhibidor de la resistencia a múltiples medicamentos y un tipo de antagonista de la glucoproteína-P. También se llama tariquidar.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateLastModified>2008-07-22</DateLastModified></GlossaryTerm>
